Edition:
United States

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

3.45USD
23 Apr 2018
Change (% chg)

$-0.01 (-0.29%)
Prev Close
$3.46
Open
$3.44
Day's High
$3.49
Day's Low
$3.30
Volume
46,184
Avg. Vol
133,151
52-wk High
$6.73
52-wk Low
$1.29

Chart for

About

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally... (more)

Overall

Beta: 2.49
Market Cap(Mil.): $122.95
Shares Outstanding(Mil.): 35.64
Dividend: --
Yield (%): --

Financials

  GALT.OQ Industry Sector
P/E (TTM): -- 185.04 32.78
EPS (TTM): -0.50 -- --
ROI: -245.84 -0.74 13.21
ROE: -- -2.80 15.01

BRIEF-Galectin Therapeutics Provides Business Update

* GALECTIN THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Mar 29 2018

BRIEF-Galectin Therapeutics Says $10 Mln Credit Line From Richard Uihlein Sufficient To Cover Expected Expenditures Into 2019

* GALECTIN THERAPEUTICS ANNOUNCES $10 MILLION CREDIT LINE FROM RICHARD E. UIHLEIN SUFFICIENT TO COVER EXPECTED EXPENDITURES INTO 2019

Dec 19 2017

Galectin slumps after NASH drug misses main goal of mid-stage trial

Galectin Therapeutics Inc said its drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a mid-stage trial, sending its shares plunging 48 percent on Tuesday.

Dec 05 2017

UPDATE 1-Galectin slumps after NASH drug misses main goal of mid-stage trial

Dec 5 Galectin Therapeutics Inc said its drug for the complex progressive fatty liver disease NASH led to some clinically meaningful results in patients with cirrhosis, but failed to achieve the main goal of a mid-stage trial, sending its shares plunging 48 percent on Tuesday.

Dec 05 2017

BRIEF-Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results

* Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results in treatment of advanced melanoma from a phase 1b clinical trial Source text for Eikon: Further company coverage:

Nov 13 2017

BRIEF-Galectin Therapeutics posts qtrly loss per share $0.13‍​

* Galectin Therapeutics Inc - ‍Top line results of NASH-CX phase 2B clinical trial expected to be announced in early December 2017​

Nov 07 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF76.04 -0.04
Merck & Co., Inc. (MRK.N) $60.25 +1.42
Roche Holding Ltd. (ROG.S) CHF217.60 +1.95
Roche Holding Ltd. (RO.S) CHF221.40 +1.40
Eli Lilly And Co (LLY.N) $80.20 +1.14
Momenta Pharmaceuticals, Inc. (MNTA.OQ) $20.10 -0.30

Earnings vs. Estimates